A woman in her seventies presented with a painful rash of 3 months’ duration, as well as fever, diaphoresis, and arthralgia of 3 weeks’ duration. The rash first appeared on the trunk with centrifugal spread to the face, arms, legs, palms, and soles. The patient had a 16-year history of untreated chronic lymphocytic leukemia, type 2 diabetes mellitus, and hypertension. Physical examination revealed reddish brown, edematous and indurated, coalescing, circular, 1- to 1.5-cm plaques on the face (leading to mild leonine facies), upper back, posterior thighs (top), buttocks (bottom), and palms. The arms, legs, abdomen, and chest also were involved to a lesser extent. The skin was diffusely tender to palpation with no accentuation over the lesions. There was no associated pruritus or lymphadenopathy. The patient was febrile (temperature, 38.4°C). A complete blood cell count with differential and liver function tests were within reference range on laboratory evaluation. Blood cultures were negative for both bacterial and fungal infections and finalized after 5 days. Polymerase chain reaction for ehrlichiosis was negative, and histoplasma and cryptococcal antigens were not detected. Computed tomography revealed a hepatic mass, splenomegaly, diffuse adenopathy, and bilateral pulmonary nodules but no parenchymal disease. Skin biopsies were obtained from the left forearm and forehead. Samples were sent to the National Hansen’s Disease (Leprosy) Program given concern for Hansen disease based on her husband’s history of prior employment in a leprosy hospital.

**WHAT’S YOUR DIAGNOSIS?**

a. amyloidosis  
b. cutaneous *Mycobacterium avium-intracellulare* complex infection  
c. leukemia cutis  
d. *Mycobacterium leprae* infection  
e. palisaded neutrophilic granulomatous dermatitis  

PLEASE TURN TO PAGE E19 FOR THE DIAGNOSIS
Histopathologic evaluation revealed superficial and deep perivascular and periadnexal inflammation. The epidermis exhibited some vacuolar interface change and effacement with relatively sparse dyskeratotic cells. A lymphohistiocytic inflammatory infiltrate surrounded the blood vessels, nerves, and adnexal structures and extended into the subcutaneous fat (Figure). Acid-fast, Grocott-Gomori methenamine-silver, Gram, Fite, *Treponema pallidum*, and Alcian blue stains were performed at our institution and were all negative. Biopsies sent to the National Hansen’s Disease (Leprosy) Program demonstrated scattered extracellular acid-fast organisms on Fite staining in the specimen of the forearm. Polymerase chain reaction testing for *Mycobacterium leprae* DNA was negative. DNA sequencing of the 16S ribosomal RNA gene matched *Mycobacterium avium-intracellulare* complex (MAC). In the workup of the hepatic mass, the patient incidentally was found to have large-cell transformation of chronic lymphocytic leukemia (CLL) and therefore was treated with bendamustine and rituximab as an outpatient. The patient received 1 chemotherapy infusion every 4 weeks for a total of 10 rounds. At 10-week follow-up after 2 rounds of chemotherapy, all of the skin lesions had resolved despite no antibiotic therapy for atypical infections.

Disseminated infection with MAC is relatively rare in healthy as well as immunocompromised individuals. Clinical disease most commonly is seen as an opportunistic infection in patients with AIDS who have CD4 counts less than 50/mm$^3$ (reference range, 500–1400/mm$^3$) or in those with preexisting lung disease.$^1$ Cutaneous involvement has been observed in only 14% of non-AIDS patients with disseminated MAC infection.$^2$ In another study of 76 patients with MAC infection, only 2 involved the skin or soft tissue.$^2$ Infection of the skin without concurrent pulmonary MAC infection is rare, though trauma may cause isolated skin infection. The cutaneous presentation of MAC infection is highly variable and may include erythematous papules, pustules, panniculitis, infiltrated plaques, verrucous lesions, and draining sinuses.$^3$ The lesions have been reported to be painful.$^1$

Cutaneous findings occur in up to 25% of patients with CLL, either due to the seeding of leukemic cells or other secondary lesions.$^4$ Leukemia cutis, or skin involvement by B-cell CLL, most commonly presents in the head and neck region as chronic and relapsing erythematous papules and plaques.$^5$ It histologically presents as monomorphic lymphocytic infiltrates accentuated around periadnexal and perivascular structures, with some extending into adipose tissue.$^2$ In our case, histopathology demonstrated a lack of monomorphous infiltrate and thus was inconsistent with leukemia cutis. Similarly, lack of pale pink deposits and lack of neutrophilic infiltrates or degenerated collagen makes amyloidosis and palisaded neutrophilic granulomatous dermatitis incorrect diagnoses, respectively.

We hypothesize that the initially undetected worsening of CLL resulted in an immunocompromised state, which facilitated this unique presentation of cutaneous MAC infection in a human immunodeficiency virus-negative patient with no clinical symptoms of active pulmonary disease. The rash was the presenting sign of both the cutaneous MAC infection and worsening CLL. Additionally, our patient’s cutaneous MAC facial...
involvement clinically resembled the leonine facies that is classic in lepromatous leprosy. Rare reports have been published addressing this similarity.  

Treatment of MAC pulmonary disease usually includes a combination of clarithromycin or azithromycin, rifampin, and ethambutol (for nodular/bronchiectatic disease), with or without amikacin or streptomycin.  

For limited pulmonary disease in patients with adequate pulmonary reserve, surgical resection may be considered in combination with the multidrug MAC pulmonary treatment regimen for 3 months to 1 year. Patients with localized MAC disease involving only the skin, soft tissue, tendons, and joints usually are treated with surgical excision in combination with clarithromycin, rifampin, and ethambutol for 6 to 12 months. In our patient, we believe that chemotherapy and the subsequent reconstituted immune system likely cleared the MAC infection without targeted antibiotic treatment.

Acknowledgments—The authors would like to thank David Scollard, MD, PhD, and Barbara Stryjewska, MD, from the National Hansen’s Disease (Leprosy) Association (Baton Rouge, Louisiana).

REFERENCES